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Abstract Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy
(TMA) characterized by the severe deficiency of a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (< 10%). Rapid
ADAMTS13 testing is crucial for an early diagnosis and optimal management of acute
TTP. We evaluated the performance of the HemosIL AcuStar ADAMTS13 activity assay
(Instrumentation Laboratory, Bedford, Massachusetts, United States), a fully automat-
ed chemiluminescent immunoassay with an analytical time of 33minutes. A method
comparison study was performed on 176 samples from 49 healthy donors and 127 TMA
patients (109 TTP, 7 atypical hemolytic uremic syndrome, 11 other TMAs), comparing
this new assay with an in-house FRETS-VWF73 assay and a commercial enzyme-linked
immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Activity, Technoclone GmbH,
Vienna, Austria). Agreement between methods was assessed with focus on ADAMTS13
activity less than 10%, the medical decision level relevant for TTP diagnosis. The
HemosIL AcuStar ADAMTS13 Activity showed good correlation with both the FRETS-
VWF73 (r¼0.96) and ELISA (r¼0.96) methods. Slope of the Passing–Bablok regression
was 1.05 for FRETS-VWF73 and 1.02 for ELISA, and absolute bias at themedical decision
level was þ0.1 and þ0.3%, respectively. The study also revealed high agreement with
FRETS-VWF73 (kappa 0.97) and ELISA (kappa 0.98) methods in classifying TTP patients
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-
threatening thromboticmicroangiopathy (TMA) characterized
by mechanical hemolytic anemia, consumption thrombocyto-
penia, and highly variable symptoms related to end-organ
ischemic damage caused by microvascular thrombosis. The
hallmark of TTP is a severe deficiency of ADAMTS13 (a dis-
integrinandmetalloproteasewith thrombospondinmotifs, 13)
activity (<10%ofnormal).Hence, itsmeasurement ispivotal to
confirm a TTP diagnosis and for optimal patient management
during acute and remission phases.1 However, the utility of
ADAMTS13 activity results is hampered by long turnaround
times.2 Thus, in most instances, the initial diagnosis of TTP
remains based on clinical criteria and therapeutic plasma
exchange (PEX) is often initiated as soon as TTP is suspected,
evenbefore themeasurementofADAMTS13activity, due to the
high mortality if the disease is left untreated.
The HemosIL AcuStar ADAMTS13 Activity assay (Instru-
mentation Laboratory, Bedford,Massachusetts, United States),
is a fully automated chemiluminescent immunoassay (CLIA)
with an analytical time of 33minutes for the quantitative
measurement of ADAMTS13 activity in human-citrated plas-
ma on the ACL AcuStar analyzer.3 The aim of this study was to
evaluate the performance of this assay in comparison to an in-
house FRETS-VWF73 assay and a commercial enzyme-linked
immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Ac-
tivity, Technoclone GmbH, Vienna, Austria).
Materials and Methods
Study Samples
The samples included in this report were analyzed in two
separate evaluation studies. The first study included the
analysis of 76 samples (21 healthy subjects, 46 TTP, 5 atypical
hemolytic uremic syndrome [aHUS], and 4 other TMAs) and
was performed during January to February 2017. The second
study was performed during June to July 2018 and included
112 samples (37 healthy subjects, 64 TTP, 4 aHUS, and 7 non-
TTP TMA)amongwhich12hadbeen testedalsoduring thefirst
study. For thepurposeof this report, the resultsobtained in the
first study for these duplicate samples were excluded, thus
leaving a total of 176 plasma samples including 49 samples
from healthy subjects (blood donors with no records of
coagulation or hemorrhagic problems), 100 with acquired
TTP (12 in the acute phase and 88 in remission), 9 with
congenital TTP, 7 with aHUS, and 11 from patients with other
TMAs. Samples were collected between 2006 and 2018 at the
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of
Fondazione IRCCS Ca’GrandaOspedaleMaggiore Policlinico in
Milan and the study was performed in accordance with the
principles of theDeclarationofHelsinki andwith the21CFR50
Protection of Human Patients and 21 CFR 56 Institutional
ReviewBoards. Sampleswere collected in3.2%buffered citrate
solution (1:9 anticoagulant:whole blood ratio) and centri-
fuged at 3,200 g for 20minutes at 4°C within 2hours of
collection. Plasma was separated, aliquoted, and stored at
–80°C until testing. Plasma aliquots were then thawed for
5minutes at 37°C prior to testing.
Laboratory Tests for ADAMTS13 Activity
The HemosIL AcuStar ADAMTS13 Activity assay is a fully
automated, two-step CLIA. Reagent cartridges include a vial
with magnetic particles coated with the VWF73 peptide
which contains the ADAMTS13 cleavage site. These particles
are incubated with the plasma sample and, after a magnetic
separation and awash step, the chemiluminescent detection
of the fragments generated by ADAMTS13 is based upon an
isoluminol-labeled monoclonal antibody that specifically
reacts with the cleaved peptide.4 After this second incuba-
tion, a magnetic separation and a wash step, reagents that
trigger the chemiluminescent reaction are added. The emit-
ted light is proportional to the ADAMTS13 activity in the
sample and is measured as relative light units by the ACL
AcuStar analyzer.3
ADAMTS13 activity was measured simultaneously in plas-
ma samples with the HemosIL AcuStar ADAMTS13 Activity
assay, the commercialELISATECHNOZYMADAMTS-13Activity,
and an in-house FRETS-VWF73 assay.5,6 All three assays
were standardized against theWorld Health Organization first
International Standard ADAMTS13 Plasma (12/252). ►Table 1
shows the main features of these assays.
Statistical Analysis
A method comparison was performed involving the three
aforementioned assays. For calculations, results in IU/mL
obtained with the TECHNOZYM ADAMTS-13 Activity ELISA
were transformed into % of normality (1 IU/mL¼100%).
Correlation was assessed using the Pearson’s method. For
quantitative comparisons, values below the lower limit of the
assay range (see►Table 1) were assigned a value equal to 50%
of this limit. Analysis was performed using the Passing–
Bablok regression to calculate the slope, intercept, and their
correspondent confidence intervals (CIs). The Bland–Altman
analysis was used to investigate systematic differences be-
tweenmethods. The agreement between the HemosIL AcuS-
tar ADAMTS13 Activity assay, the FRETS-VWF73 assay, or the
TECHNOZYMADAMTS-13 Activity ELISA to classify results as
lower than 10%, that is, themedical decision level relevant for
a TTP diagnosis, was assessed using kappa statistics. Analyze-
it v4.60 (Analyze-it Software, Ltd, Leeds, United Kingdom)
was used for calculations.
with a severe deficiency of ADAMTS13 activity. Because of its short turnaround time
and full automation, the HemosIL AcuStar ADAMTS13 activity assay might become the
assay of choice to rapidly test ADAMTS13 activity in plasma and thus establish the
diagnosis of acute TTP in emergency settings.
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Results
Comparison of HemosIL AcuStar ADAMTS13 Activity
versus In-House FRETS-VWF73
Agoodcorrelationwasobtained for the 176 samples (r¼0.956,
95%CI: 0.942–0.967,p<0.0001) (►Fig. 1A, upper panel). Slope
and intercept values of the Passing–Bablok regression were
1.05 (95% CI: 0.99–1.14) and –0.41 (95% CI: –1.36 to 2.05),
respectively. Absolute bias at 10% of ADAMTS13 activity was
þ0.1%, with a 95% CI of –0.6 to 2.4% (i.e., an expected value of
9.4–12.4% ADAMTS13 activity). Bland–Altman analysis
showed a mean bias of –15.9% (95% CI: –26.2 to –5.6%), with
Table 1 Main features of the ADAMTS13 activity assays
FRETS-VWF73 TECHNOZYM ADAMTS-13
Activity ELISAa
HemosIL AcuStar
ADAMTS13 Activity
Substrate FRETS-VWF73 GST-VWF73 GST-VWF73-His
Detection method Fluorescent:
direct detection of VWF
cleavage products
Chromogenic:
immune-detection of VWF
cleavage products by specific mAb
Chemiluminescent:
immune-detection of VWF
cleavage products by specific mAb
Detection limit 3.3% 0.002 IU/mL (0.2%) 0.2%
Assay range 3.3–105% 0.003–1.05 IU/mL (0.3–105%) 0.2–150%b
Intra-assay precision (CV) 6.0%  5.4%  4.4%
Interassay precision (CV) 9.5%  8.0%  5.1%
Normal range 45–147% 0.40–1.30 IU/mL (40–130%) 67–129%
Assay lengthc 1 hour  3.5 hours 33 minutes
Abbreviations: CV, coefficient of variation; mAb, monoclonal antibody; VWF, von Willebrand factor.
aPackage insert information.
bThe quantitation limit of the HemosIL AcuStar ADAMTS13 Activity assay was revised to a final value of 0.2% after validation studies completion.
cConsidering only the time needed to run the assay, excluding sample and calibrator dilution and data analysis.
Fig. 1 Results of the comparison between assays. (A) Comparison between HemosIL AcuStar ADAMTS13 Activity (HemosIL) and in-house FRETS-VWF73
(FRET). Upper panel, the Passing–Bablok regression plot. Dashed line: fitted regression line y¼ –0.41þ 1.05 . Lower panel, the Bland–Altman plot. Solid
line: mean bias¼ –15.9%; dashed lines: 95% limits of agreement –152 to 120%. (B) Comparison between HemosIL AcuStar ADAMTS13 Activity (HemosIL)
and TECHNOZYM ADAMTS-13 Activity ELISA (TECHNOZYM). Upper panel, the Passing–Bablok regression plot. Dashed line: fitted regression line
y¼ 0.05þ 1.02 . Lower panel, the Bland–Altman plot. Solid line: mean bias¼ 2.9%; dashed lines: 95% limits of agreement –60 to 66%.
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limits of agreement (LoA) of –152 and 120% (►Fig. 1A, lower
panel). This result indicates that, onaverage, theHemosIL assay
reports lower activity values than the FRETS-VWF73 assay.
However, this was due to samples with ADAMTS13 activity
levels below the limit of quantitation of the FRETS-VWF73
assay. Indeed, when the analysis was restricted to the 139
samples with measurable activity levels, the mean bias was
12.3% (95%CI: 7.3–17.3%), reflecting anaverageoverestimation
by the HemosIL assay. This was especially observed in the
intermediate-lowactivity range (from the limit of quantitation
to 70%) (►Fig. 1A, lower panel). Finally, the study revealed high
agreement (kappa¼0.97) between the HemosIL AcuStar
ADAMTS13Activityand the FRETS-VWF73assays in classifying
samples with severe deficiency (< 10%) of ADAMTS13 activity
(►Table 2).
Comparison of HemosIL AcuStar ADAMTS13 Activity
versus TECHNOZYM ADAMTS-13 Activity
Correlation was good (r¼0.957, 95% CI: 0.943–0.968,
p<0.0001) between the TECHNOZYM ADAMTS-13 Activity
ELISA and the HemosIL AcuStar ADAMTS13 Activity for the
176 samples included in this study (►Fig. 1B, upper panel).
Slope and intercept values of the Passing–Bablok regression
were 1.02 (95% CI: 0.99–1.07) and 0.05 (95% CI: –0.06 to
0.25), respectively. Absolute bias at 10% of ADAMTS13 activ-
ity was 0.3%, with a 95% CI of –0.05 to 0.7 (i.e., an expected
value of 10.0–10.7% ADAMTS13 activity). The Bland–Altman
analysis revealed a mean bias of 2.9% (95% CI: –1.8 to 7.7%),
with LoA of –60 and 66% (►Fig. 1B, lower panel). A trend for
the HemosIL assay to underestimate activity values in the
high assay range (> 110%) was observed. A high degree of
agreement (kappa¼0.98) was obtained between the Hemo-
sIL AcuStar ADAMTS13 Activity assay and the commercial
ELISA in classifying samples with<10% ADAMTS13 activity
(►Table 2).
Diagnostic Accuracy and Analytical Sensitivity of
HemosIL AcuStar ADAMTS13 Activity
►Fig. 2 shows the distribution of the HemosIL AcuStar
ADAMTS13 Activity results according to the corresponding
clinical diagnosis for the 176 plasma samples analyzed.
Concordantly with FRETS-VWF73 and TECHNOZYM
ADAMTS-13 Activity, the HemosIL AcuStar ADAMTS13 Ac-
tivity assay reported severely reduced levels of ADAMTS13
activity (<10%) for all patientswith acquired TTP in the acute
phase and for all but one patient with congenital TTP
(HemosIL AcuStar ADAMTS13 Activity 11.4%, TECHNOZYM
ADAMTS-13 Activity 6.6%, and FRETS-VWF73 3.4%). Concor-
dance between assays was observed in the detection of
ADAMTS13 activity levels in all but one patientwith acquired
TTP in the remission phase (HemosIL AcuStar ADAMTS13
Activity 11.3%, TECHNOZYM ADAMTS-13 Activity 10.6%, and
FRETS-VWF73 4.3%), in healthy donors and in patients with
aHUS or other TMAs.
The detection capability of the HemosIL AcuStar
ADAMTS13 Activity assay allowed better resolution of the
very lowADAMTS13 activity samples in comparisonwith the
FRETS-VWF73 (►Fig. 3). Forty-four samples included in the
study gave ADAMTS13 activity levels below 10% with the
three methods. The HemosIL AcuStar ADAMTS13 Activity
allowed measurement of ADAMTS13 activity in 31 of them
(70%) to a minimum value of 0.2%, in comparison with 16
samples (36%) for the TECHNOZYM ADAMTS-13 Activity to a
minimum value of 0.2% and 7 samples (16%) for the FRETS-
VWF73 to a minimum value of 3.3%.
Discussion
In this study,we evaluated the performance of a newmethod,
the HemosIL AcuStar ADAMTS13 Activity assay, in a large
population of patients with TTP, aHUS, other TMAs, and in
healthy controls. The new assay showed significant correla-
tion with the in-house FRETS-VWF73 assay and the TECH-
NOZYM ADAMTS-13 Activity ELISA. At Passing–Bablok
Fig. 2 Distribution of results of HemosIL AcuStar ADAMTS13 Activity
according to thediagnosis. Dashed lines show themeanADAMTS13activity
value obtained for each group of samples. The 10% ADAMTS13 activity
level, used to define the cutoff for severe ADAMTS13 activity deficiency, is
also shown (gray area). (A) Acquired thrombotic thrombocytopenic pur-
pura (TTP) in acute phase. (B) Acquired TTP in remission phase. (C)
Congenital TTP. (D) atypical hemolytic uremic syndrome (aHUS). (E) Other
thrombotic microangiopathies (TMAs). (F) Normal.
Table 2 Agreement between HemosIL AcuStar ADAMTS13 Activity with FRETS-VWF73 and TECHNOZYM ADAMTS-13 Activity
ELISA
FRETS-VWF73 TECHNOZYM ADAMTS-13 Activity ELISA
HemosIL AcuStar
ADAMTS13 Activity
< 10%
(n¼ 46)
10%
(n¼130)
< 10%
(n¼45)
 10%
(n¼131)
< 10% (n¼ 44) 44 0 44 0
 10% (n¼ 132) 2 130 1 131
Kappa coefficient 0.97 0.98
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regression analysis, no constant differences and good com-
parability with both methods were observed. Moreover, the
HemosIL AcuStar ADAMTS13 Activity assay showed a high
agreement with the FRETS-VWF73 and TECHNOZYM assays
in detecting ADAMTS13 activity levels below 10%, which
define the internationally accepted cutoff for a diagnosis of
severe ADAMTS13 deficiency typical of TTP.1
The analytical performance of the HemosIL AcuStar
ADAMTS13 Activity assay in comparison with the TECHNO-
ZYM ADAMTS-13 Activity assay has already been evaluated
by Favresse et al in a relatively small series of 38 plasma
samples from patients with severe (n¼8), moderate (n¼2),
and normal (n¼28) ADAMTS13 activity levels.7 The authors
reported on average lower levels as measured by the Hemo-
sIL assay (mean difference of HemosIL and TECHNOZYM
assay results: –4.8% [95% CI: –9.83 to 0.27%]). This is some-
what in contrast with our findings,which indicate on average
higher levels as measured by the HemosIL assay (mean bias
2.9% [95% CI: –1.8 to 7.7%]). Differences in the reagent lots
and in the type and number of samples tested (the full range
of ADAMTS13 activity values is more represented in our
study) may explain this minor difference. Most importantly,
as in our study, Favresse et al found a full agreement between
the two assays in detecting severe ADAMTS13 deficiency,
with no misclassification and a bias close to zero when
considering only ADAMTS13 activity values below 10%.7
TTP is a life-threatening condition often presenting with
rapid and severe progression, and thereby shouldbediagnosed
and treated in emergency with PEX, as soon as it is suspected.
The rather long turnaround times and complex execution of
commonly usedmethods for ADAMTS13measurement, which
include the FRETS-VWF73 and TECHNOZYM ADAMTS-13
Activity assays, often lead clinicians to decision-making in
situations of emergency without the support of ADAMTS13
test results. Although the HemosIL assay requires the AcuStar
instrumentation, which has a rather limited diffusion in com-
parison with spectrophotometric devices, the more rapid
turnaround time of this assay favors a prompt and accurate
diagnosis. More certainty regarding an accurate diagnosis of
TTP using this assay would also, in addition to the use of PEX,
allow consideration for the early use of caplacizumab,with the
related potential benefits.8
Our study has limitations. First, our sample population
has been collected between 2006 and 2018, raising the issue
of a potential differential effect of prolonged frozen storage
on ADAMTS13 activity measurements obtained with the
three analyzed assays. However, the vast majority of samples
(85%) were stored for less than 3 years, 52% for less than
1 year. No difference in the correlation analysis was observed
after stratification on the basis of the duration of storage
(►Supplementary Table S1, available in the online version).
Another limitation of our study is that we did not measure
ADAMTS13 activity on fresh plasma samples, as it would be
done in emergency settings. Although this does not invali-
date the comparisons herein performed, we are unable to
establish whether testing fresh or biobanked frozen samples
would differentially affect the ADAMTS13 activity results
obtained by the three assays. Further studies are required to
investigate this issue.
In conclusion, the results reported herewith indicate that
full automation and short turnaround time of the new
HemosIL AcuStar ADAMTS13 Activity assay provide impor-
tant characteristics for use in emergency settings, even in
hospital laboratories without specialized personnel.
What is known about this topic?
• Thrombotic thrombocytopenic purpura is a rare, life-
threatening thrombotic microangiopathy characterized
by the severe deficiency of ADAMTS13 activity (< 10%).
What does this paper add?
• The performance of the fully automated HemosIL
AcuStar ADAMTS13 activity assay with an analytical
time of 33minutes was evaluated.
• The new assay showed excellent clinical performance
in detecting severe ADAMTS13 deficiency and good
correlation with in-house FRETS-VWF73 assay and
TECHNOZYM ADAMTS-13 Activity ELISA.
• Acute thrombotic thrombocytopenic purpura diagno-
sis in emergency setting can benefit from this assay.
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